Evidence map›Paper›PMID 40765842›Full record

ArticleMultiple sclerosis journal - experimental, translational and clinical

Delays in treatment initiation for patients with relapsing-remitting multiple sclerosis-A nationwide population-based study.

Maiju Savolainen, Matias Viitala, Katariina Kuutti, Hanna Kuusisto, Ilkka Rauma, Mervi Ryytty, Johanna Krüger, Päivi Hartikainen, Marja Niiranen, Jukka Saarinen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maiju SavolainenDepartment of Neurology, Brain center, Helsinki University Hospital and Clinical Neurosciences, University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0009-0009-1483-0279
Matias ViitalaStellarQ Ltd, Turku, Finland.ORCID https://orcid.org/0000-0003-2854-2410
Katariina KuuttiClinical Neurosciences, Neurocenter, University of Turku and Turku University Hospital, Turku, Finland.ORCID https://orcid.org/0000-0001-9642-2598
Hanna KuusistoDepartment of Neurology, Tampere University Hospital, Tampere, Finland; Department of Health and Social Management, University of Eastern Finland, Kuopio, Finland.ORCID https://orcid.org/0000-0002-3697-4961
Ilkka RaumaNeural Medicine Responsibility Sector, Department of Sensory, Neural, and Musculosceletal Medicine, Neurocenter Finland, Tampere Brain and Mind, Wellbeing Services County of Pirkanmaa, Tampere University Hospital, Tampere, Finland; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.ORCID https://orcid.org/0000-0002-3275-9631
Mervi RyyttyResearch Unit of Clinical Medicine Neurology and Oulu University Hospital, Neurocenter, Neurology and MRC, University of Oulu, Oulu, Finland.ORCID https://orcid.org/0009-0003-3814-371X
Johanna KrügerResearch Unit of Clinical Medicine Neurology and Oulu University Hospital, Neurocenter, Neurology and MRC, University of Oulu, Oulu, Finland.ORCID https://orcid.org/0000-0003-4346-1133
Päivi HartikainenNeuro Center, Neurology, Kuopio University Hospital, Kuopio, Finland.ORCID https://orcid.org/0000-0003-4081-9216
Marja NiiranenNeuro Center, Neurology, Kuopio University Hospital, Kuopio, Finland.ORCID https://orcid.org/0000-0001-8674-020X
Jukka SaarinenNeurology Departments, Wellbeing Services County of Ostrobothnia, Vaasa, Finland.ORCID https://orcid.org/0000-0001-6312-6573
Merja Soilu-HänninenClinical Neurosciences, Neurocenter, University of Turku and Turku University Hospital, Turku, Finland.ORCID https://orcid.org/0000-0001-6930-0229
Sini M LaaksoDepartment of Neurology, Brain center, Helsinki University Hospital and Clinical Neurosciences, University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0002-0104-2849

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Early disease-modifying therapy (DMT) improves outcomes in patients with relapsing-remitting multiple sclerosis (pwRRMS), but reasons for delayed or absent initiation are unclear. Objective: To investigate reasons and trends for delayed or absent DMT initiation among Finnish pwRRMS. Methods: A nationwide retrospective study using the Finnish MS Registry identified 2363 pwRRMS diagnosed between 2010 and 2019 in the participating centers. Patients never receiving DMT or starting >2 years post-diagnosis were compared to those initiating DMT within a year of diagnosis. Results: We identified 193 pwRRMS who never started DMT, 88 had delayed initiation over 2 years, and 1944 started within a year. The no/delayed DMT group was older at diagnosis (mean 38.7 vs 35.2 years, Conclusion: Delayed or absent DMT initiation is linked to older age, optic neuritis, disease inactivity, and treatment refusal, which declined over time, likely due to expanded DMT options.

Indexed as

disease-modifying therapiesMultiple sclerosispatient refusalregistry-based studyrelapsing-remittingtreatment delay

Identifiers

PMID40765842
PMCPMC12322356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.